Enzymatica AB (publ) (ENZY.ST)
SEK 3.4
(7.94%)
SEK 3.4
(7.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -41.12 Million SEK | 31.43% |
| 2022 | -59.97 Million SEK | -57.06% |
| 2021 | -38.18 Million SEK | -630.39% |
| 2020 | -5.22 Million SEK | 84.85% |
| 2019 | -33.39 Million SEK | 0.15% |
| 2018 | -33.58 Million SEK | -38.38% |
| 2017 | -24.97 Million SEK | 45.35% |
| 2016 | -42.6 Million SEK | -13.18% |
| 2015 | -40.38 Million SEK | -27.78% |
| 2014 | -31.8 Million SEK | -97.36% |
| 2013 | -16.04 Million SEK | -113.05% |
| 2012 | -7.54 Million SEK | -53.39% |
| 2011 | -4.9 Million SEK | 0.0% |
| 2009 | -72.81 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -18.38 Million SEK | -35.6% |
| 2024 Q2 | -13.5 Million SEK | 27.73% |
| 2023 Q3 | -8.74 Million SEK | 20.47% |
| 2023 Q4 | -13.55 Million SEK | -54.96% |
| 2023 FY | - SEK | 31.43% |
| 2023 Q1 | -14.29 Million SEK | 34.23% |
| 2023 Q2 | -10.99 Million SEK | 23.07% |
| 2022 Q3 | -12.43 Million SEK | 20.18% |
| 2022 Q4 | -21.73 Million SEK | -74.83% |
| 2022 FY | - SEK | -57.06% |
| 2022 Q1 | -18 Million SEK | -70.16% |
| 2022 Q2 | -15.57 Million SEK | 13.46% |
| 2021 Q2 | -20 Million SEK | -140.03% |
| 2021 Q4 | -10.57 Million SEK | -78.65% |
| 2021 FY | - SEK | -630.39% |
| 2021 Q1 | -8.33 Million SEK | -15930.77% |
| 2021 Q3 | -5.92 Million SEK | 70.41% |
| 2020 Q1 | 1.11 Million SEK | 115.61% |
| 2020 Q4 | -52 Thousand SEK | 97.03% |
| 2020 Q3 | -1.75 Million SEK | 84.86% |
| 2020 Q2 | -11.57 Million SEK | -1136.83% |
| 2020 FY | - SEK | 84.85% |
| 2019 FY | - SEK | 0.15% |
| 2019 Q4 | -7.14 Million SEK | -0.27% |
| 2019 Q2 | -15.34 Million SEK | -31.56% |
| 2019 Q1 | -11.66 Million SEK | -57.68% |
| 2019 Q3 | -7.12 Million SEK | 53.56% |
| 2018 Q4 | -7.39 Million SEK | 18.34% |
| 2018 FY | - SEK | -38.38% |
| 2018 Q3 | -9.06 Million SEK | 38.61% |
| 2018 Q2 | -14.76 Million SEK | -54.14% |
| 2018 Q1 | -9.57 Million SEK | -92.17% |
| 2017 FY | - SEK | 45.35% |
| 2017 Q4 | -4.98 Million SEK | -127.43% |
| 2017 Q1 | -11.43 Million SEK | 37.84% |
| 2017 Q2 | -11.8 Million SEK | -3.26% |
| 2017 Q3 | -2.19 Million SEK | 81.44% |
| 2016 Q2 | -12.15 Million SEK | -57.71% |
| 2016 Q3 | -7.44 Million SEK | 38.78% |
| 2016 Q4 | -18.39 Million SEK | -147.17% |
| 2016 Q1 | -7.7 Million SEK | 30.76% |
| 2016 FY | - SEK | -13.18% |
| 2015 Q3 | -9.86 Million SEK | 5.22% |
| 2015 FY | - SEK | -27.78% |
| 2015 Q4 | -11.13 Million SEK | -12.81% |
| 2015 Q1 | -8.96 Million SEK | 24.86% |
| 2015 Q2 | -10.41 Million SEK | -16.11% |
| 2014 Q4 | -11.93 Million SEK | -105.49% |
| 2014 Q1 | -6.42 Million SEK | -35.21% |
| 2014 Q3 | -5.8 Million SEK | 21.99% |
| 2014 Q2 | -7.44 Million SEK | -15.95% |
| 2014 FY | - SEK | -97.36% |
| 2013 Q2 | -3.49 Million SEK | -39.35% |
| 2013 Q4 | -4.74 Million SEK | 9.77% |
| 2013 FY | - SEK | -113.05% |
| 2013 Q3 | -5.26 Million SEK | -50.56% |
| 2013 Q1 | -2.5 Million SEK | -16.83% |
| 2012 FY | - SEK | -53.39% |
| 2012 Q3 | 1.96 Million SEK | 175.81% |
| 2012 Q2 | -2.59 Million SEK | -48.01% |
| 2012 Q1 | -1.75 Million SEK | 0.0% |
| 2012 Q4 | -2.14 Million SEK | -209.24% |
| 2011 Q2 | -1.29 Million SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q3 | -1.46 Million SEK | -13.07% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | -209.71 Thousand SEK | 0.0% |
| 2010 Q3 | -421.65 Thousand SEK | -101.07% |
| 2009 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -200.358% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | -8.593% |
| BioGaia AB (publ) | 466.19 Million SEK | 108.821% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 4.485% |
| Gabather AB (publ) | 37 Thousand SEK | 111240.541% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -178.416% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | -52.533% |
| Nanexa AB (publ) | -70.79 Million SEK | 41.911% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -233.241% |
| ODI Pharma AB | 1.36 Million SEK | 3107.395% |
| Orexo AB (publ) | -22 Million SEK | -86.918% |
| Probi AB (publ) | 115.61 Million SEK | 135.569% |
| Swedencare AB (publ) | 484 Million SEK | 108.496% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.568% |
| Toleranzia AB | -7.39 Million SEK | -455.853% |
| Vivesto AB | -89.75 Million SEK | 54.186% |